nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CYP2D6—Vinorelbine—ovarian cancer	0.0415	0.213	CbGbCtD
Methazolamide—CYP3A4—Topotecan—ovarian cancer	0.0375	0.192	CbGbCtD
Methazolamide—CYP2C9—Paclitaxel—ovarian cancer	0.0319	0.164	CbGbCtD
Methazolamide—CYP3A4—Vinorelbine—ovarian cancer	0.0264	0.135	CbGbCtD
Methazolamide—CYP3A4—Paclitaxel—ovarian cancer	0.0186	0.0952	CbGbCtD
Methazolamide—CYP2D6—Doxorubicin—ovarian cancer	0.0157	0.0807	CbGbCtD
Methazolamide—CYP3A4—Docetaxel—ovarian cancer	0.0134	0.0688	CbGbCtD
Methazolamide—Bone marrow depression—Melphalan—ovarian cancer	0.0121	0.0156	CcSEcCtD
Methazolamide—Electrolyte imbalance—Paclitaxel—ovarian cancer	0.0115	0.0148	CcSEcCtD
Methazolamide—Bone marrow depression—Vinorelbine—ovarian cancer	0.0106	0.0136	CcSEcCtD
Methazolamide—Vertigo—Altretamine—ovarian cancer	0.0104	0.0134	CcSEcCtD
Methazolamide—Leukopenia—Altretamine—ovarian cancer	0.0103	0.0133	CcSEcCtD
Methazolamide—Tingling sensation—Melphalan—ovarian cancer	0.0102	0.0131	CcSEcCtD
Methazolamide—Convulsion—Altretamine—ovarian cancer	0.01	0.0129	CcSEcCtD
Methazolamide—CYP3A4—Doxorubicin—ovarian cancer	0.01	0.0513	CbGbCtD
Methazolamide—Anorexia—Altretamine—ovarian cancer	0.00899	0.0116	CcSEcCtD
Methazolamide—Hepatic necrosis—Paclitaxel—ovarian cancer	0.00828	0.0106	CcSEcCtD
Methazolamide—Decreased appetite—Altretamine—ovarian cancer	0.0082	0.0105	CcSEcCtD
Methazolamide—Fatigue—Altretamine—ovarian cancer	0.00813	0.0105	CcSEcCtD
Methazolamide—Haemolytic anaemia—Chlorambucil—ovarian cancer	0.00756	0.00972	CcSEcCtD
Methazolamide—Asthenia—Altretamine—ovarian cancer	0.00677	0.0087	CcSEcCtD
Methazolamide—Aplastic anaemia—Vinorelbine—ovarian cancer	0.00672	0.00864	CcSEcCtD
Methazolamide—Haemolytic anaemia—Melphalan—ovarian cancer	0.00659	0.00847	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Chlorambucil—ovarian cancer	0.00614	0.0079	CcSEcCtD
Methazolamide—Vomiting—Altretamine—ovarian cancer	0.006	0.00771	CcSEcCtD
Methazolamide—Tingling sensation—Paclitaxel—ovarian cancer	0.00599	0.0077	CcSEcCtD
Methazolamide—Polyuria—Vinorelbine—ovarian cancer	0.00592	0.00761	CcSEcCtD
Methazolamide—Hepatic failure—Vinorelbine—ovarian cancer	0.00578	0.00743	CcSEcCtD
Methazolamide—Blood disorder—Paclitaxel—ovarian cancer	0.00576	0.00741	CcSEcCtD
Methazolamide—Nausea—Altretamine—ovarian cancer	0.0056	0.0072	CcSEcCtD
Methazolamide—Pancytopenia—Chlorambucil—ovarian cancer	0.0056	0.0072	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Chlorambucil—ovarian cancer	0.00521	0.0067	CcSEcCtD
Methazolamide—Body temperature increased—Carboplatin—ovarian cancer	0.00515	0.00663	CcSEcCtD
Methazolamide—Pancytopenia—Topotecan—ovarian cancer	0.00498	0.00641	CcSEcCtD
Methazolamide—Pancytopenia—Melphalan—ovarian cancer	0.00488	0.00628	CcSEcCtD
Methazolamide—Melaena—Paclitaxel—ovarian cancer	0.0047	0.00605	CcSEcCtD
Methazolamide—Erythema multiforme—Chlorambucil—ovarian cancer	0.00446	0.00574	CcSEcCtD
Methazolamide—Urine output increased—Paclitaxel—ovarian cancer	0.00435	0.0056	CcSEcCtD
Methazolamide—Pancytopenia—Vinorelbine—ovarian cancer	0.00426	0.00548	CcSEcCtD
Methazolamide—Bone marrow depression—Epirubicin—ovarian cancer	0.00408	0.00524	CcSEcCtD
Methazolamide—Polyuria—Paclitaxel—ovarian cancer	0.00398	0.00512	CcSEcCtD
Methazolamide—Bone marrow depression—Doxorubicin—ovarian cancer	0.00377	0.00485	CcSEcCtD
Methazolamide—Agranulocytosis—Vinorelbine—ovarian cancer	0.00374	0.0048	CcSEcCtD
Methazolamide—Leukopenia—Chlorambucil—ovarian cancer	0.00368	0.00473	CcSEcCtD
Methazolamide—Convulsion—Chlorambucil—ovarian cancer	0.00356	0.00458	CcSEcCtD
Methazolamide—Glycosuria—Epirubicin—ovarian cancer	0.0034	0.00437	CcSEcCtD
Methazolamide—Ill-defined disorder—Topotecan—ovarian cancer	0.00339	0.00436	CcSEcCtD
Methazolamide—Confusional state—Chlorambucil—ovarian cancer	0.00338	0.00435	CcSEcCtD
Methazolamide—Malaise—Topotecan—ovarian cancer	0.0033	0.00424	CcSEcCtD
Methazolamide—Hepatic failure—Docetaxel—ovarian cancer	0.0033	0.00424	CcSEcCtD
Methazolamide—Blood disorder—Epirubicin—ovarian cancer	0.0033	0.00424	CcSEcCtD
Methazolamide—Leukopenia—Topotecan—ovarian cancer	0.00327	0.00421	CcSEcCtD
Methazolamide—Leukopenia—Melphalan—ovarian cancer	0.00321	0.00412	CcSEcCtD
Methazolamide—Anorexia—Chlorambucil—ovarian cancer	0.0032	0.00411	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Paclitaxel—ovarian cancer	0.00315	0.00405	CcSEcCtD
Methazolamide—Glycosuria—Doxorubicin—ovarian cancer	0.00314	0.00404	CcSEcCtD
Methazolamide—Convulsion—Melphalan—ovarian cancer	0.0031	0.00399	CcSEcCtD
Methazolamide—Discomfort—Topotecan—ovarian cancer	0.00308	0.00396	CcSEcCtD
Methazolamide—Blood disorder—Doxorubicin—ovarian cancer	0.00305	0.00392	CcSEcCtD
Methazolamide—Anaphylactic shock—Topotecan—ovarian cancer	0.00298	0.00384	CcSEcCtD
Methazolamide—Dyspepsia—Chlorambucil—ovarian cancer	0.00295	0.00379	CcSEcCtD
Methazolamide—Anaphylactic shock—Melphalan—ovarian cancer	0.00292	0.00376	CcSEcCtD
Methazolamide—Decreased appetite—Chlorambucil—ovarian cancer	0.00291	0.00375	CcSEcCtD
Methazolamide—Ill-defined disorder—Vinorelbine—ovarian cancer	0.0029	0.00373	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00289	0.00372	CcSEcCtD
Methazolamide—Fatigue—Chlorambucil—ovarian cancer	0.00289	0.00372	CcSEcCtD
Methazolamide—Pancytopenia—Paclitaxel—ovarian cancer	0.00287	0.00369	CcSEcCtD
Methazolamide—Anorexia—Topotecan—ovarian cancer	0.00285	0.00366	CcSEcCtD
Methazolamide—CA5A—female reproductive system—ovarian cancer	0.00285	0.105	CbGeAlD
Methazolamide—Malaise—Vinorelbine—ovarian cancer	0.00282	0.00363	CcSEcCtD
Methazolamide—Vertigo—Vinorelbine—ovarian cancer	0.00281	0.00361	CcSEcCtD
Methazolamide—Leukopenia—Vinorelbine—ovarian cancer	0.0028	0.0036	CcSEcCtD
Methazolamide—Anorexia—Melphalan—ovarian cancer	0.00279	0.00358	CcSEcCtD
Methazolamide—Feeling abnormal—Chlorambucil—ovarian cancer	0.00276	0.00355	CcSEcCtD
Methazolamide—Photosensitivity reaction—Paclitaxel—ovarian cancer	0.00276	0.00354	CcSEcCtD
Methazolamide—Melaena—Epirubicin—ovarian cancer	0.00269	0.00346	CcSEcCtD
Methazolamide—Paraesthesia—Topotecan—ovarian cancer	0.00268	0.00345	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Paclitaxel—ovarian cancer	0.00267	0.00343	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Docetaxel—ovarian cancer	0.00267	0.00343	CcSEcCtD
Methazolamide—Urticaria—Chlorambucil—ovarian cancer	0.00266	0.00342	CcSEcCtD
Methazolamide—Body temperature increased—Chlorambucil—ovarian cancer	0.00265	0.00341	CcSEcCtD
Methazolamide—Discomfort—Vinorelbine—ovarian cancer	0.00263	0.00338	CcSEcCtD
Methazolamide—Dyspepsia—Topotecan—ovarian cancer	0.00263	0.00338	CcSEcCtD
Methazolamide—Paraesthesia—Melphalan—ovarian cancer	0.00262	0.00337	CcSEcCtD
Methazolamide—Decreased appetite—Topotecan—ovarian cancer	0.00259	0.00334	CcSEcCtD
Methazolamide—Aplastic anaemia—Epirubicin—ovarian cancer	0.00258	0.00332	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00258	0.00331	CcSEcCtD
Methazolamide—Fatigue—Topotecan—ovarian cancer	0.00257	0.00331	CcSEcCtD
Methazolamide—Dyspepsia—Melphalan—ovarian cancer	0.00257	0.00331	CcSEcCtD
Methazolamide—Haematuria—Paclitaxel—ovarian cancer	0.00257	0.0033	CcSEcCtD
Methazolamide—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00255	0.00328	CcSEcCtD
Methazolamide—Decreased appetite—Melphalan—ovarian cancer	0.00254	0.00327	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00252	0.00324	CcSEcCtD
Methazolamide—Fatigue—Melphalan—ovarian cancer	0.00252	0.00324	CcSEcCtD
Methazolamide—Melaena—Doxorubicin—ovarian cancer	0.00249	0.0032	CcSEcCtD
Methazolamide—Feeling abnormal—Topotecan—ovarian cancer	0.00246	0.00316	CcSEcCtD
Methazolamide—Anorexia—Vinorelbine—ovarian cancer	0.00243	0.00313	CcSEcCtD
Methazolamide—Pancytopenia—Docetaxel—ovarian cancer	0.00243	0.00313	CcSEcCtD
Methazolamide—Asthenia—Chlorambucil—ovarian cancer	0.00241	0.00309	CcSEcCtD
Methazolamide—Aplastic anaemia—Doxorubicin—ovarian cancer	0.00239	0.00307	CcSEcCtD
Methazolamide—Urticaria—Topotecan—ovarian cancer	0.00237	0.00305	CcSEcCtD
Methazolamide—Body temperature increased—Topotecan—ovarian cancer	0.00236	0.00303	CcSEcCtD
Methazolamide—Urticaria—Melphalan—ovarian cancer	0.00232	0.00299	CcSEcCtD
Methazolamide—Diarrhoea—Chlorambucil—ovarian cancer	0.00229	0.00295	CcSEcCtD
Methazolamide—Paraesthesia—Vinorelbine—ovarian cancer	0.00229	0.00295	CcSEcCtD
Methazolamide—Erythema multiforme—Paclitaxel—ovarian cancer	0.00229	0.00294	CcSEcCtD
Methazolamide—Photosensitivity—Epirubicin—ovarian cancer	0.00228	0.00293	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.00226	0.00291	CcSEcCtD
Methazolamide—Tinnitus—Paclitaxel—ovarian cancer	0.00225	0.0029	CcSEcCtD
Methazolamide—Hepatic failure—Epirubicin—ovarian cancer	0.00222	0.00286	CcSEcCtD
Methazolamide—Decreased appetite—Vinorelbine—ovarian cancer	0.00222	0.00285	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.0022	0.00283	CcSEcCtD
Methazolamide—Fatigue—Vinorelbine—ovarian cancer	0.0022	0.00283	CcSEcCtD
Methazolamide—Asthenia—Topotecan—ovarian cancer	0.00214	0.00275	CcSEcCtD
Methazolamide—Vomiting—Chlorambucil—ovarian cancer	0.00213	0.00274	CcSEcCtD
Methazolamide—Agranulocytosis—Docetaxel—ovarian cancer	0.00213	0.00274	CcSEcCtD
Methazolamide—Photosensitivity—Doxorubicin—ovarian cancer	0.00211	0.00271	CcSEcCtD
Methazolamide—Feeling abnormal—Vinorelbine—ovarian cancer	0.0021	0.00271	CcSEcCtD
Methazolamide—Asthenia—Melphalan—ovarian cancer	0.0021	0.0027	CcSEcCtD
Methazolamide—Dysgeusia—Paclitaxel—ovarian cancer	0.00206	0.00265	CcSEcCtD
Methazolamide—Hepatic failure—Doxorubicin—ovarian cancer	0.00206	0.00264	CcSEcCtD
Methazolamide—Diarrhoea—Topotecan—ovarian cancer	0.00204	0.00263	CcSEcCtD
Methazolamide—Urticaria—Vinorelbine—ovarian cancer	0.00203	0.00261	CcSEcCtD
Methazolamide—Body temperature increased—Vinorelbine—ovarian cancer	0.00202	0.0026	CcSEcCtD
Methazolamide—Diarrhoea—Melphalan—ovarian cancer	0.002	0.00257	CcSEcCtD
Methazolamide—Nausea—Chlorambucil—ovarian cancer	0.00199	0.00256	CcSEcCtD
Methazolamide—Ill-defined disorder—Paclitaxel—ovarian cancer	0.00195	0.00251	CcSEcCtD
Methazolamide—Erythema multiforme—Docetaxel—ovarian cancer	0.00194	0.00249	CcSEcCtD
Methazolamide—Vomiting—Topotecan—ovarian cancer	0.0019	0.00244	CcSEcCtD
Methazolamide—Malaise—Paclitaxel—ovarian cancer	0.0019	0.00244	CcSEcCtD
Methazolamide—Vertigo—Paclitaxel—ovarian cancer	0.00189	0.00243	CcSEcCtD
Methazolamide—Leukopenia—Paclitaxel—ovarian cancer	0.00188	0.00242	CcSEcCtD
Methazolamide—Rash—Topotecan—ovarian cancer	0.00188	0.00242	CcSEcCtD
Methazolamide—Dermatitis—Topotecan—ovarian cancer	0.00188	0.00242	CcSEcCtD
Methazolamide—Headache—Topotecan—ovarian cancer	0.00187	0.0024	CcSEcCtD
Methazolamide—Vomiting—Melphalan—ovarian cancer	0.00186	0.00239	CcSEcCtD
Methazolamide—Rash—Melphalan—ovarian cancer	0.00184	0.00237	CcSEcCtD
Methazolamide—Dermatitis—Melphalan—ovarian cancer	0.00184	0.00237	CcSEcCtD
Methazolamide—Asthenia—Vinorelbine—ovarian cancer	0.00183	0.00236	CcSEcCtD
Methazolamide—Convulsion—Paclitaxel—ovarian cancer	0.00182	0.00234	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.0018	0.00231	CcSEcCtD
Methazolamide—Nausea—Topotecan—ovarian cancer	0.00177	0.00228	CcSEcCtD
Methazolamide—Discomfort—Paclitaxel—ovarian cancer	0.00177	0.00228	CcSEcCtD
Methazolamide—Diarrhoea—Vinorelbine—ovarian cancer	0.00175	0.00225	CcSEcCtD
Methazolamide—Dysgeusia—Docetaxel—ovarian cancer	0.00175	0.00225	CcSEcCtD
Methazolamide—Nausea—Melphalan—ovarian cancer	0.00174	0.00223	CcSEcCtD
Methazolamide—Confusional state—Paclitaxel—ovarian cancer	0.00173	0.00223	CcSEcCtD
Methazolamide—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00172	0.00221	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.00166	0.00214	CcSEcCtD
Methazolamide—CA9—female reproductive system—ovarian cancer	0.00166	0.0612	CbGeAlD
Methazolamide—Pancytopenia—Epirubicin—ovarian cancer	0.00164	0.00211	CcSEcCtD
Methazolamide—Anorexia—Paclitaxel—ovarian cancer	0.00164	0.0021	CcSEcCtD
Methazolamide—Vomiting—Vinorelbine—ovarian cancer	0.00162	0.00209	CcSEcCtD
Methazolamide—Rash—Vinorelbine—ovarian cancer	0.00161	0.00207	CcSEcCtD
Methazolamide—Dermatitis—Vinorelbine—ovarian cancer	0.00161	0.00207	CcSEcCtD
Methazolamide—Headache—Vinorelbine—ovarian cancer	0.0016	0.00206	CcSEcCtD
Methazolamide—Leukopenia—Docetaxel—ovarian cancer	0.0016	0.00205	CcSEcCtD
Methazolamide—Photosensitivity reaction—Epirubicin—ovarian cancer	0.00158	0.00203	CcSEcCtD
Methazolamide—Convulsion—Docetaxel—ovarian cancer	0.00155	0.00199	CcSEcCtD
Methazolamide—Paraesthesia—Paclitaxel—ovarian cancer	0.00154	0.00198	CcSEcCtD
Methazolamide—Drowsiness—Epirubicin—ovarian cancer	0.00154	0.00198	CcSEcCtD
Methazolamide—Somnolence—Paclitaxel—ovarian cancer	0.00153	0.00196	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.00153	0.00196	CcSEcCtD
Methazolamide—Pancytopenia—Doxorubicin—ovarian cancer	0.00152	0.00195	CcSEcCtD
Methazolamide—Nausea—Vinorelbine—ovarian cancer	0.00152	0.00195	CcSEcCtD
Methazolamide—Dyspepsia—Paclitaxel—ovarian cancer	0.00151	0.00194	CcSEcCtD
Methazolamide—Decreased appetite—Paclitaxel—ovarian cancer	0.00149	0.00192	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00148	0.00191	CcSEcCtD
Methazolamide—Fatigue—Paclitaxel—ovarian cancer	0.00148	0.0019	CcSEcCtD
Methazolamide—Haematuria—Epirubicin—ovarian cancer	0.00147	0.00189	CcSEcCtD
Methazolamide—Confusional state—Docetaxel—ovarian cancer	0.00147	0.00189	CcSEcCtD
Methazolamide—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.00146	0.00187	CcSEcCtD
Methazolamide—Anaphylactic shock—Docetaxel—ovarian cancer	0.00146	0.00187	CcSEcCtD
Methazolamide—Agranulocytosis—Epirubicin—ovarian cancer	0.00144	0.00185	CcSEcCtD
Methazolamide—Drowsiness—Doxorubicin—ovarian cancer	0.00142	0.00183	CcSEcCtD
Methazolamide—Feeling abnormal—Paclitaxel—ovarian cancer	0.00142	0.00182	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.00141	0.00182	CcSEcCtD
Methazolamide—Anorexia—Docetaxel—ovarian cancer	0.00139	0.00178	CcSEcCtD
Methazolamide—Urticaria—Paclitaxel—ovarian cancer	0.00136	0.00175	CcSEcCtD
Methazolamide—Haematuria—Doxorubicin—ovarian cancer	0.00136	0.00175	CcSEcCtD
Methazolamide—Body temperature increased—Paclitaxel—ovarian cancer	0.00136	0.00175	CcSEcCtD
Methazolamide—CA9—testis—ovarian cancer	0.00134	0.0494	CbGeAlD
Methazolamide—Agranulocytosis—Doxorubicin—ovarian cancer	0.00133	0.00171	CcSEcCtD
Methazolamide—Paraesthesia—Docetaxel—ovarian cancer	0.00131	0.00168	CcSEcCtD
Methazolamide—Erythema multiforme—Epirubicin—ovarian cancer	0.00131	0.00168	CcSEcCtD
Methazolamide—Somnolence—Docetaxel—ovarian cancer	0.00129	0.00166	CcSEcCtD
Methazolamide—Tinnitus—Epirubicin—ovarian cancer	0.00129	0.00166	CcSEcCtD
Methazolamide—Dyspepsia—Docetaxel—ovarian cancer	0.00128	0.00165	CcSEcCtD
Methazolamide—Decreased appetite—Docetaxel—ovarian cancer	0.00127	0.00163	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00126	0.00162	CcSEcCtD
Methazolamide—Fatigue—Docetaxel—ovarian cancer	0.00126	0.00161	CcSEcCtD
Methazolamide—CA5B—gonad—ovarian cancer	0.00124	0.0455	CbGeAlD
Methazolamide—Asthenia—Paclitaxel—ovarian cancer	0.00123	0.00158	CcSEcCtD
Methazolamide—CA12—female reproductive system—ovarian cancer	0.00123	0.0453	CbGeAlD
Methazolamide—Erythema multiforme—Doxorubicin—ovarian cancer	0.00121	0.00155	CcSEcCtD
Methazolamide—Feeling abnormal—Docetaxel—ovarian cancer	0.0012	0.00154	CcSEcCtD
Methazolamide—Tinnitus—Doxorubicin—ovarian cancer	0.00119	0.00153	CcSEcCtD
Methazolamide—Dysgeusia—Epirubicin—ovarian cancer	0.00118	0.00151	CcSEcCtD
Methazolamide—Diarrhoea—Paclitaxel—ovarian cancer	0.00118	0.00151	CcSEcCtD
Methazolamide—Body temperature increased—Docetaxel—ovarian cancer	0.00115	0.00148	CcSEcCtD
Methazolamide—Ill-defined disorder—Epirubicin—ovarian cancer	0.00112	0.00144	CcSEcCtD
Methazolamide—CA5B—female reproductive system—ovarian cancer	0.0011	0.0406	CbGeAlD
Methazolamide—Vomiting—Paclitaxel—ovarian cancer	0.00109	0.0014	CcSEcCtD
Methazolamide—Dysgeusia—Doxorubicin—ovarian cancer	0.00109	0.0014	CcSEcCtD
Methazolamide—Malaise—Epirubicin—ovarian cancer	0.00108	0.00139	CcSEcCtD
Methazolamide—Rash—Paclitaxel—ovarian cancer	0.00108	0.00139	CcSEcCtD
Methazolamide—Dermatitis—Paclitaxel—ovarian cancer	0.00108	0.00139	CcSEcCtD
Methazolamide—Vertigo—Epirubicin—ovarian cancer	0.00108	0.00139	CcSEcCtD
Methazolamide—Leukopenia—Epirubicin—ovarian cancer	0.00108	0.00138	CcSEcCtD
Methazolamide—Headache—Paclitaxel—ovarian cancer	0.00108	0.00138	CcSEcCtD
Methazolamide—Asthenia—Docetaxel—ovarian cancer	0.00104	0.00134	CcSEcCtD
Methazolamide—Convulsion—Epirubicin—ovarian cancer	0.00104	0.00134	CcSEcCtD
Methazolamide—CA2—embryo—ovarian cancer	0.00104	0.0383	CbGeAlD
Methazolamide—Ill-defined disorder—Doxorubicin—ovarian cancer	0.00103	0.00133	CcSEcCtD
Methazolamide—Nausea—Paclitaxel—ovarian cancer	0.00102	0.00131	CcSEcCtD
Methazolamide—Discomfort—Epirubicin—ovarian cancer	0.00101	0.0013	CcSEcCtD
Methazolamide—Malaise—Doxorubicin—ovarian cancer	0.001	0.00129	CcSEcCtD
Methazolamide—Vertigo—Doxorubicin—ovarian cancer	0.001	0.00129	CcSEcCtD
Methazolamide—CA5B—vagina—ovarian cancer	0.000998	0.0367	CbGeAlD
Methazolamide—Leukopenia—Doxorubicin—ovarian cancer	0.000996	0.00128	CcSEcCtD
Methazolamide—Diarrhoea—Docetaxel—ovarian cancer	0.000996	0.00128	CcSEcCtD
Methazolamide—Confusional state—Epirubicin—ovarian cancer	0.00099	0.00127	CcSEcCtD
Methazolamide—Anaphylactic shock—Epirubicin—ovarian cancer	0.000982	0.00126	CcSEcCtD
Methazolamide—CA1—female reproductive system—ovarian cancer	0.000974	0.0359	CbGeAlD
Methazolamide—Convulsion—Doxorubicin—ovarian cancer	0.000965	0.00124	CcSEcCtD
Methazolamide—Discomfort—Doxorubicin—ovarian cancer	0.000936	0.0012	CcSEcCtD
Methazolamide—Anorexia—Epirubicin—ovarian cancer	0.000936	0.0012	CcSEcCtD
Methazolamide—Vomiting—Docetaxel—ovarian cancer	0.000926	0.00119	CcSEcCtD
Methazolamide—CA1—bone marrow—ovarian cancer	0.00092	0.0339	CbGeAlD
Methazolamide—Rash—Docetaxel—ovarian cancer	0.000918	0.00118	CcSEcCtD
Methazolamide—Dermatitis—Docetaxel—ovarian cancer	0.000917	0.00118	CcSEcCtD
Methazolamide—Confusional state—Doxorubicin—ovarian cancer	0.000916	0.00118	CcSEcCtD
Methazolamide—Headache—Docetaxel—ovarian cancer	0.000912	0.00117	CcSEcCtD
Methazolamide—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000909	0.00117	CcSEcCtD
Methazolamide—CA5B—testis—ovarian cancer	0.00089	0.0328	CbGeAlD
Methazolamide—Paraesthesia—Epirubicin—ovarian cancer	0.000882	0.00113	CcSEcCtD
Methazolamide—Somnolence—Epirubicin—ovarian cancer	0.000873	0.00112	CcSEcCtD
Methazolamide—Anorexia—Doxorubicin—ovarian cancer	0.000866	0.00111	CcSEcCtD
Methazolamide—Nausea—Docetaxel—ovarian cancer	0.000865	0.00111	CcSEcCtD
Methazolamide—Dyspepsia—Epirubicin—ovarian cancer	0.000864	0.00111	CcSEcCtD
Methazolamide—Decreased appetite—Epirubicin—ovarian cancer	0.000854	0.0011	CcSEcCtD
Methazolamide—CA2—epithelium—ovarian cancer	0.00085	0.0313	CbGeAlD
Methazolamide—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000848	0.00109	CcSEcCtD
Methazolamide—Fatigue—Epirubicin—ovarian cancer	0.000847	0.00109	CcSEcCtD
Methazolamide—Paraesthesia—Doxorubicin—ovarian cancer	0.000816	0.00105	CcSEcCtD
Methazolamide—Feeling abnormal—Epirubicin—ovarian cancer	0.000809	0.00104	CcSEcCtD
Methazolamide—Somnolence—Doxorubicin—ovarian cancer	0.000808	0.00104	CcSEcCtD
Methazolamide—CA2—decidua—ovarian cancer	0.000803	0.0296	CbGeAlD
Methazolamide—Dyspepsia—Doxorubicin—ovarian cancer	0.0008	0.00103	CcSEcCtD
Methazolamide—Decreased appetite—Doxorubicin—ovarian cancer	0.00079	0.00102	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000784	0.00101	CcSEcCtD
Methazolamide—Fatigue—Doxorubicin—ovarian cancer	0.000783	0.00101	CcSEcCtD
Methazolamide—Urticaria—Epirubicin—ovarian cancer	0.00078	0.001	CcSEcCtD
Methazolamide—Body temperature increased—Epirubicin—ovarian cancer	0.000776	0.000998	CcSEcCtD
Methazolamide—CA4—female reproductive system—ovarian cancer	0.000761	0.028	CbGeAlD
Methazolamide—Feeling abnormal—Doxorubicin—ovarian cancer	0.000749	0.000963	CcSEcCtD
Methazolamide—Urticaria—Doxorubicin—ovarian cancer	0.000722	0.000928	CcSEcCtD
Methazolamide—CA4—bone marrow—ovarian cancer	0.000719	0.0265	CbGeAlD
Methazolamide—Body temperature increased—Doxorubicin—ovarian cancer	0.000718	0.000923	CcSEcCtD
Methazolamide—Asthenia—Epirubicin—ovarian cancer	0.000704	0.000906	CcSEcCtD
Methazolamide—CA4—female gonad—ovarian cancer	0.000693	0.0255	CbGeAlD
Methazolamide—Diarrhoea—Epirubicin—ovarian cancer	0.000672	0.000864	CcSEcCtD
Methazolamide—Asthenia—Doxorubicin—ovarian cancer	0.000652	0.000838	CcSEcCtD
Methazolamide—CA5B—lymph node—ovarian cancer	0.000645	0.0238	CbGeAlD
Methazolamide—CA2—female reproductive system—ovarian cancer	0.000631	0.0232	CbGeAlD
Methazolamide—Vomiting—Epirubicin—ovarian cancer	0.000624	0.000803	CcSEcCtD
Methazolamide—CYP2C19—vagina—ovarian cancer	0.000623	0.0229	CbGeAlD
Methazolamide—Diarrhoea—Doxorubicin—ovarian cancer	0.000622	0.000799	CcSEcCtD
Methazolamide—Rash—Epirubicin—ovarian cancer	0.000619	0.000796	CcSEcCtD
Methazolamide—Dermatitis—Epirubicin—ovarian cancer	0.000619	0.000795	CcSEcCtD
Methazolamide—Headache—Epirubicin—ovarian cancer	0.000615	0.000791	CcSEcCtD
Methazolamide—CA4—testis—ovarian cancer	0.000614	0.0226	CbGeAlD
Methazolamide—CA2—bone marrow—ovarian cancer	0.000596	0.0219	CbGeAlD
Methazolamide—Nausea—Epirubicin—ovarian cancer	0.000583	0.00075	CcSEcCtD
Methazolamide—Vomiting—Doxorubicin—ovarian cancer	0.000578	0.000743	CcSEcCtD
Methazolamide—CA2—female gonad—ovarian cancer	0.000574	0.0211	CbGeAlD
Methazolamide—Rash—Doxorubicin—ovarian cancer	0.000573	0.000736	CcSEcCtD
Methazolamide—Dermatitis—Doxorubicin—ovarian cancer	0.000572	0.000736	CcSEcCtD
Methazolamide—CA2—vagina—ovarian cancer	0.000571	0.021	CbGeAlD
Methazolamide—CA1—lymph node—ovarian cancer	0.00057	0.021	CbGeAlD
Methazolamide—Headache—Doxorubicin—ovarian cancer	0.000569	0.000732	CcSEcCtD
Methazolamide—Nausea—Doxorubicin—ovarian cancer	0.00054	0.000694	CcSEcCtD
Methazolamide—CYP2C9—female reproductive system—ovarian cancer	0.000534	0.0197	CbGeAlD
Methazolamide—CA2—testis—ovarian cancer	0.000509	0.0188	CbGeAlD
Methazolamide—CYP2E1—female reproductive system—ovarian cancer	0.000506	0.0186	CbGeAlD
Methazolamide—CA4—lymph node—ovarian cancer	0.000445	0.0164	CbGeAlD
Methazolamide—CYP2E1—testis—ovarian cancer	0.000408	0.015	CbGeAlD
Methazolamide—CYP3A4—female reproductive system—ovarian cancer	0.000407	0.015	CbGeAlD
Methazolamide—CYP2D6—female reproductive system—ovarian cancer	0.000401	0.0148	CbGeAlD
Methazolamide—CA2—lymph node—ovarian cancer	0.000369	0.0136	CbGeAlD
Methazolamide—CYP2D6—female gonad—ovarian cancer	0.000365	0.0134	CbGeAlD
Methazolamide—CYP2D6—testis—ovarian cancer	0.000323	0.0119	CbGeAlD
